Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported FCF Margin over the past 9 years, most recently at 1600.49% for Q4 2025.

  • For Q4 2025, FCF Margin changed N/A year-over-year to 1600.49%; the TTM value through Dec 2025 reached 4985.5%, up 1718717.0%, while the annual FY2025 figure was 4985.5%, 1718717.0% up from the prior year.
  • FCF Margin for Q4 2025 was 1600.49% at Crinetics Pharmaceuticals, up from 77404.2% in the prior quarter.
  • Over five years, FCF Margin peaked at 432.55% in Q1 2022 and troughed at 77404.2% in Q3 2025.
  • A 5-year average of 12454.06% and a median of 7338.17% in 2022 define the central range for FCF Margin.
  • On a YoY basis, FCF Margin climbed as much as 416213bps in 2025 and fell as far as -1629007bps in 2025.
  • Year by year, FCF Margin stood at 2125.88% in 2021, then crashed by -144bps to 5190.83% in 2022, then tumbled by -151bps to 13021.1% in 2023, then increased by 4bps to 12471.93% in 2024, then surged by 87bps to 1600.49% in 2025.
  • Business Quant data shows FCF Margin for CRNX at 1600.49% in Q4 2025, 77404.2% in Q3 2025, and 8309.8% in Q2 2025.